Early access
Sign in
CompletedPhase 2

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

Key facts

Who runs it
Evommune, Inc.
Where
Asheville, Austin, Baltimore, Baton Rouge, Birmingham, Boardman, Boston, Canal Winchester, Charlotte, Cincinnati, Cypress, El Paso, Fort Myers, Fremont, Greenfield, Hutchinson, Lafayette, Lancaster, Layton, Lexington, Louisville, Mobile, Myrtle Beach, New Orleans, Normal, North Charleston, Northridge, Northville, Plainfield, Prosper, Santa Rosa, Seattle, Smyrna, Statesville, Tampa, Toledo, Upland, Ventura, West Des Moines, Wildwood, and Woodbury, United StatesSee the 41 sitesAlso in 2 other countries, 12 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
182 people enrolled
Started
20 Mar 2025
Ended
5 Jun 2026
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • EVO756
  • Placebo control
Record updated
1 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Confirmed CSU diagnosis for at least 3 months with an inadequate response to H1-antihistamines
  • Subjects who are taking H1-antihistamines must be on a stable regimen 4 weeks prior to Day 1 and while on study
  • Urticaria Activity Score (UAS7) equal to or greater than 16 at Day 1. UAS entries must be completed for a minimum of 4 out of the 7 days prior to Day 1

Who cannot take part

  • Use of certain medications
  • History of diseases with urticaria or angioedema symptoms, other than CSU and symptomatic dermographism
  • Significant medical history other than CSU, or any other condition which might interfere with the evaluation of CSU
  • Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening, according to the Investigator's discretion

Where in United States

Also in 2 other countries, 12 sites

  • Allergy Partners Clinical ResearchAsheville, United States
  • Austin Regional Clinic ARC Clinical ResearchAustin, United States
  • Johns Hopkins Bayview Medical CenterBaltimore, United States
  • Delricht Research LouisianaBaton Rouge, United States
  • Cahaba Dermatology Skin Health CenterBirmingham, United States
  • Optima Research BoardmanBoardman, United States
  • Boston SpecialistsBoston, United States
  • DOCS Dermatology ResearchCanal Winchester, United States
  • Delricht Research - Priority CareCharlotte, United States
  • Bernstein Clinical Research CenterCincinnati, United States
  • Studies in DermatologyCypress, United States
  • Western Sky Medical ResearchEl Paso, United States
  • AMR Fort MyersFort Myers, United States
  • Center for Dermatology Clinical ResearchFremont, United States
  • Allergy, Asthma, and Sinus CenterGreenfield, United States
  • Hutchinson ClinicHutchinson, United States
  • Velocity Clinical Research, LafayetteLafayette, United States
  • Antelope Valley Clinical TrialsLancaster, United States
  • AMR UtahLayton, United States
  • Bluegrass Allergy CareLexington, United States
  • Delricht Research LouisvilleLouisville, United States
  • Velocity Clinical Research, MobileMobile, United States
  • AMR Myrtle BeachMyrtle Beach, United States
  • Delricht ResearchNew Orleans, United States
  • Sneeze, Wheeze, & Itch Associates LLCNormal, United States
  • National Allergy and Asthma ResearchNorth Charleston, United States
  • Northridge Clinical TrialsNorthridge, United States
  • MI Skin InnovationsNorthville, United States
  • The Indiana Clinical Trials CenterPlainfield, United States
  • Delricht Research - Lockhard Matter DermatologyProsper, United States
  • NorthBay Clinical ResearchSanta Rosa, United States
  • Seattle Clinical Research CenterSeattle, United States
  • Delricht Research - SmyrnaSmyrna, United States
  • Piedmont HealthcareStatesville, United States
  • Advanced Clinical Research InstituteTampa, United States
  • Toledo Institute of Clinical ResearchToledo, United States
  • Integrated Research of InlandUpland, United States
  • FOMAT Medical ResearchVentura, United States
  • The Iowa ClinicWest Des Moines, United States
  • DelRicht Research - Town Center DermatologyWildwood, United States
  • Vitality Clinical TrialsWoodbury, United States

About the trial

What the trial wants to find out

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).

The 4 groups in the trial

  • Dose 1Treatment being tested

    Orally administered EVO756, dose 1

    Treatment: EVO756

  • Dose 2Treatment being tested

    Orally administered EVO756, dose 2

    Treatment: EVO756

  • Dose 3Treatment being tested

    Orally administered EVO756, dose 3

    Treatment: EVO756

  • Placebo controlPlacebo, for comparison

    Orally administered placebo control

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria
Record updated
1 July 2026